摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

CVT-5440 | 531506-64-6

中文名称
——
中文别名
——
英文名称
CVT-5440
英文别名
8-(4-{[5-(3-methoxyphenyl)(1,2,4-oxadiazol-3-yl)]methoxy}phenyl)-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione;8-{4-[5-(3-methoxyphenyl)-[1,2,4]oxadiazol-3-ylmethoxy]phenyl}-1,3-dipropyl-1,3,7-trihydropurine-2,6-dione;8-[4-[[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7H-purine-2,6-dione
CVT-5440化学式
CAS
531506-64-6
化学式
C27H28N6O5
mdl
——
分子量
516.557
InChiKey
AHJHSANRNGKAFS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    770.1±70.0 °C(Predicted)
  • 密度:
    1.292±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.7
  • 重原子数:
    38
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    127
  • 氢给体数:
    1
  • 氢受体数:
    8

SDS

SDS:af1300759b15b3f2a90a3a39a9179585
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    间甲氧基苯甲酰氯盐酸potassium carbonateN,N-二异丙基乙胺 作用下, 以 乙醇二氯甲烷丙酮甲苯 为溶剂, 反应 66.0h, 生成 CVT-5440
    参考文献:
    名称:
    The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma
    摘要:
    Adenosine has been suggested to play a role in asthma, possibly via activation of A(2B) adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A(2B) AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A(2B) AdoR antagonist with good selectivity (A(2B) AdoR K-i = 50 nM, selectivity A(1) > 200: A(2A) > 200: A(3) > 167). (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.11.044
点击查看最新优质反应信息

文献信息

  • Method of wound healing using A2B adenosine receptor antagonists
    申请人:Zeng Dewan
    公开号:US20060058322A1
    公开(公告)日:2006-03-16
    The present invention relates to methods of wound healing using A 2B adenosine receptor antagonists. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    本发明涉及使用A2B腺苷受体拮抗剂进行伤口愈合的方法。该发明还涉及制备此类化合物的方法,以及包含它们的药物组合物。
  • METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS
    申请人:Zeng Dewan
    公开号:US20070219221A1
    公开(公告)日:2007-09-20
    The invention is related to methods of preventing and treating hepatic fibrosis using A 2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.
    本发明涉及使用A2B腺苷受体拮抗剂预防和治疗肝纤维化的方法,以及在治疗和预防因酒精滥用、外科手术干预、病毒性肝炎、摄入肝毒性药物或其他肝脏疾病引起的肝脏损伤中的用途。本发明还涉及用于该方法的药物组合物。
  • Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
    申请人:Belardinelli Luiz
    公开号:US20120003329A1
    公开(公告)日:2012-01-05
    This disclosure relates generally to treating patients having pulmonary hypertension, or symptoms associated therewith, by administering a therapeutically effective amount of an A 2B receptor antagonist to the patient.
    本公开涉及通过向患者施用治疗有效量的A2B受体拮抗剂来治疗患有肺动脉高压或与之相关的症状的患者。
  • [EN] XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE XANTHINE SERVANT D'ANTAGONISTES DU RECEPTEUR DE L'ADENOSINE A2B
    申请人:CV THERAPEUTICS INC
    公开号:WO2004106337A1
    公开(公告)日:2004-12-09
    Disclosed are compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.
    揭示了一种A2B腺苷受体拮抗剂化合物,可用于治疗包括哮喘和腹泻在内的各种疾病状态。
  • A2B adenosine receptor antagonists
    申请人:Kalla Rao
    公开号:US20050101778A1
    公开(公告)日:2005-05-12
    Disclosed are novel A 2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
    揭示了具有Formula I或Formula II结构的新型A2B腺苷受体拮抗剂:这些化合物特别适用于治疗哮喘、炎症性胃肠道疾病、心血管疾病、神经系统疾病以及与不良血管生成相关的疾病。
查看更多